[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020

November 2020 | 56 pages | ID: C54594E8554EN
GlobalData

US$ 2,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020

SUMMARY

GlobalData's Medical Devices sector report, “Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020' provides comprehensive information about the Cervical Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Cervical Cancer Diagnostic Tests are used for detection of cancer based on the detection and measurement of cancer-specific biomarker/antibody/antigen present in patient’s sample.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

SCOPE
  • Extensive coverage of the Cervical Cancer Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Cervical Cancer Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
REASONS TO BUY

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Cervical Cancer Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Cervical Cancer Overview

3 PRODUCTS UNDER DEVELOPMENT

3.1 Cervical Cancer - Pipeline Products by Stage of Development
3.2 Cervical Cancer - Pipeline Products by Territory
3.3 Cervical Cancer - Pipeline Products by Regulatory Path
3.4 Cervical Cancer - Pipeline Products by Estimated Approval Date

4 CERVICAL CANCER - PIPELINE PRODUCTS UNDER DEVELOPMENT BY COMPANIES

4.1 Cervical Cancer Companies - Pipeline Products by Stage of Development
4.2 Cervical Cancer - Pipeline Products by Stage of Development

5 CERVICAL CANCER COMPANIES AND PRODUCT OVERVIEW

6 CERVICAL CANCER- RECENT DEVELOPMENTS

6.1 Oct 26, 2020: Cervical cancer study compares Dalrada Health VIA screening kits to pap smear, peer reviewed journal - The Gynecologist - publishes findings
6.2 Jul 31, 2020: New Cervical Cancer Screening Guidelines from the American Cancer Society risk reversing decades of progress made against Cervical Cancer
6.3 Jun 24, 2020: Cancer Genetics reports first quarter 2020 financial results and provides strategic business updates
6.4 Mar 12, 2020: Roche gets FDA approval for cytology test to prevent cervical cancer
6.5 Feb 26, 2020: MDxHealth reports financial year 2019 results and provides outlook for 2020
6.6 Feb 06, 2020: BD announces results for 2020 first fiscal quarter; lowers fiscal 2020 guidance
6.7 Jan 30, 2020: Quest Diagnostics reports record fourth quarter and full year 2019 revenues and earnings; provides guidance for full year 2020; increases dividend 5.7% to $0.56 per quarter
6.8 Jan 30, 2020: Genomic Vision: Financial information for the fourth quarter of 2019
6.9 Nov 20, 2019: Cancer Genetics reports third quarter 2019 financial results and provides strategic business update
6.10 Nov 12, 2019: Cancer Research UK appoints new Executive Director of Fundraising and Marketing

7 APPENDIX

7.1 Methodology
7.2 About GlobalData
7.3 Contact Us

LIST OF TABLES

Table 1: Cervical Cancer - Pipeline Products by Stage of Development
Table 2: Cervical Cancer - Pipeline Products by Territory
Table 3: Cervical Cancer - Pipeline Products by Regulatory Path
Table 4: Cervical Cancer - Pipeline Products by Estimated Approval Date
Table 5: Cervical Cancer Companies - Pipeline Products by Stage of Development
Table 6: Cervical Cancer - Pipeline Products by Stage of Development
Table 7: Alere Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 8: NMP179 Test - Product Status
Table 9: NMP179 Test - Product Description
Table 10: Augusta University Pipeline Products & Ongoing Clinical Trials Overview
Table 11: Folate Receptor Biomarker Test - Cervical Cancer - Product Status
Table 12: Folate Receptor Biomarker Test - Cervical Cancer - Product Description
Table 13: Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview
Table 14: BD SurePath Plus Molecular Pap Test System - Product Status
Table 15: BD SurePath Plus Molecular Pap Test System - Product Description
Table 16: Bio Techne Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 17: RNAscope HPV Assay - Cervical Cancer - Product Status
Table 18: RNAscope HPV Assay - Cervical Cancer - Product Description
Table 19: BioAffinity Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 20: CyPath Diagnostic Assay - Cervical Cancer - Product Status
Table 21: CyPath Diagnostic Assay - Cervical Cancer - Product Description
Table 22: BioMark Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 23: Metabolomics-based Diagnostic Assay - Cervical Cancer - Product Status
Table 24: Metabolomics-based Diagnostic Assay - Cervical Cancer - Product Description
Table 25: BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 26: Biomarker Assay - Cervical Cancer - Product Status
Table 27: Biomarker Assay - Cervical Cancer - Product Description
Table 28: Cepheid Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 29: Xpert Molecular PAP Assay - Product Status
Table 30: Xpert Molecular PAP Assay - Product Description
Table 31: China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Diagnostic Kit - Carcinoma Cervix - Product Status
Table 33: Diagnostic Kit - Carcinoma Cervix - Product Description
Table 34: Cytosystems Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 35: Laboratory-Based Diagnostic Test - Cervical Cancer - Product Status
Table 36: Laboratory-Based Diagnostic Test - Cervical Cancer - Product Description
Table 37: Enzo Biochem Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 38: p16 Biomarker - Cervical cancer - Product Status
Table 39: p16 Biomarker - Cervical cancer - Product Description
Table 40: Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 41: Liquid Biopsy Test - Cervical Cancer - Product Status
Table 42: Liquid Biopsy Test - Cervical Cancer - Product Description
Table 43: GenomicTree Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 44: EarlyTect Cervical Cancer - Product Status
Table 45: EarlyTect Cervical Cancer - Product Description
Table 46: Screening Test - Cervical Cancer - Product Status
Table 47: Screening Test - Cervical Cancer - Product Description
Table 48: GRANT Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview

LIST OF FIGURES

Figure 1: Cervical Cancer - Pipeline Products by Stage of Development
Figure 2: Cervical Cancer - Pipeline Products by Territory
Figure 3: Cervical Cancer - Pipeline Products by Regulatory Path
Figure 4: Cervical Cancer - Pipeline Products by Estimated Approval Date


More Publications